CDT Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 30.93%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $1,446,981.00

Conduit Pharmaceuticals Insider Trading History Chart

Conduit Pharmaceuticals Share Price & Price History

^$0.91

▼ -0.1599 (-14.94%)

As of 04/11/2025 05:00 PM ET

Days: 30 | 90 | 365

Conduit Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/7/2024	Ltd Nirland	Major Shareholder	Sell	9,390	$10.00	$93,900.00	60,920
10/4/2024	Ltd Nirland	Major Shareholder	Sell	13,689	$10.00	$136,890.00	70,310
10/2/2024	Ltd Nirland	Major Shareholder	Sell	3,331	$10.00	$33,310.00	99,000
9/30/2024	Ltd Nirland	Major Shareholder	Sell	10,168	$12.00	$122,016.00	114,831
7/17/2024	Andrew Regan	Director	Sell	15,141	$26.00	$393,666.00	1,776
7/15/2024	Andrew Regan	Director	Sell	10,052	$25.00	$251,300.00	119,361
7/12/2024	Andrew Regan	Director	Sell	13,898	$25.00	$347,450.00	129,413
7/10/2024	Andrew Regan	Director	Sell	1,500	$33.00	$49,500.00	152,140
7/8/2024	Andrew Regan	Director	Sell	359	$51.00	$18,309.00	154,417
7/3/2024	Andrew Regan	Director	Sell	10	$64.00	$640.00	154,776

See Full Table

SEC Filings (Institutional Ownership Changes) for Conduit Pharmaceuticals (NASDAQ:CDT)

3.29% of Conduit Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Conduit Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	Citadel Advisors LLC	526,268	$36K	0.0%	+177.0%	51.094%
2/13/2025	Barclays PLC	892,350	$61K	0.0%	+6.5%	86.636%
2/12/2025	Geode Capital Management LLC	584,984	$40K	0.0%	+36.8%	56.795%
1/30/2025	Rhumbline Advisers	1,028,702	$71K	0.0%	+5,034.0%	1.000%

Data available starting January 2016

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Today's Range

Now: $0.91

$0.90

$1.40

50 Day Range

MA: $1.12

$0.59

$2.85

52 Week Range

Now: $0.91

$0.51

$350.00

Volume

40,039,260 shs

Average Volume

1,534,157 shs

Market Capitalization

$6.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.37

Who are the company insiders with the largest holdings of Conduit Pharmaceuticals?: Conduit Pharmaceuticals' top insider investors include:
Andrew Regan (Director)
Ltd Nirland (Major Shareholder)
Learn More about top insider investors at Conduit Pharmaceuticals.